Saturday, February 6, 2016

GlaxoSmithKline's China troubles not going away anytime soon

China's Security Ministry said Thursday that several GlaxoSmithKline executives based in the country had confessed to charges of bribery and tax law violations, Reuters reported.

GlaxoSmithKline's China troubles not going away anytime soon

0 comments

China's Security Ministry said Thursday that several GlaxoSmithKline executives based in the country had confessed to charges of bribery and tax law violations, Reuters reported. Link here.

The bribes were offered to Chinese government officials, medical associations, hospitals and doctors to boost sales and prices, the ministry said in a statement on its website, according to Reuters.

GSK declined to comment on the number or nationality of the staff members involved.

"We take all allegations of bribery and corruption seriously," GSK said in a statement. "We continuously monitor our businesses to ensure they meet our strict compliance procedures - we have done this in China and found no evidence of bribery or corruption of doctors or government officials."

GSK is based in London, but has operations at Philadelphia's Navy Yard and in the region's suburbs.

Some of the trouble relates to sale of Botox, the skin enhancement medication. Allergan makes Botox and in 2005 struck a deal with GSK to market the drug in China.

 

Staff Writer
0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com or 215-854-4506.

David Sell Staff Writer
Also on Philly.com:
letter icon Newsletter